2011’s biggest patent expiries

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

2011’s biggest patent expiries

Home/Policies & Legislation | Posted 22/04/2011 0 Post your comment

2011 looks set to be a bumper year for generics, with patents from some of the biggest selling drugs set to expire.

Just looking at the top five selling drugs, US sales of more than US$10 billion will be open to competition by the generics industry.

Key patent expiries, according to data from EvaluatePharma, include Lipitor (atorvastatin – Pfizer), Zyprexa (olanzapine – Eli Lilly), Levaquin (levofloxacin – Johnson & Johnson), Concerta (methylphenidate – Johnson & Johnson) and Protonix (pantoprazole – Pfizer). These patent expiries, while being very good news for the generics industry and patients could deal a major blow to some of the largest pharmaceutical companies.

In 2010, with US$10.8 billion in worldwide sales, Lipitor accounted for 15.8% of Pfizer’s total revenue. While in 2010, Zyprexa’s worldwide revenues were just over US$5 billion, or nearly 22% of Eli Lilly’s full year sales.

Once drugs lose patent protection, lower-price generics rapidly gain market share, often siphoning off as much as 90% of sales. Benefits to patients are substantial, with generics averaging about 30% of the price of the brand-name originals.

Related article

2012’s biggest patent expiries

Source: EvaluatePharma

Comments (0)

Post your comment

Guidelines

WHO’s revised guideline to safe and effective biosimilar products

New FDA guidance on statistical approaches to establishing bioequivalence

Foro latinoamericano

map

Reports

The successful uptake of biosimilars in Europe and the US

Biosimilar monoclonal antibodies in China

Most viewed articles

The best selling biotechnology drugs of 2008: the next biosimilars targets

Global biosimilars guideline development – EGA’s perspective

EU guidelines for biosimilars

Related content

The effects of regulation on innovation in Mexican pharmaceutical industry

FDA publishes BsUFA III research roadmap

The US Biologics Competition Act and Biosimilar Red Tape Elimination Act

EU public consultation on revised framework for compulsory licensing of patents

Related content

The effects of regulation on innovation in Mexican pharmaceutical industry

Regulation V13H16

Home/Policies & Legislation Posted 09/03/2023

FDA publishes BsUFA III research roadmap

Harmonize V13F28

Home/Policies & Legislation Posted 03/03/2023

The US Biologics Competition Act and Biosimilar Red Tape Elimination Act

19646665_l

Home/Policies & Legislation Posted 27/01/2023

EU public consultation on revised framework for compulsory licensing of patents

15 AA010699

Home/Policies & Legislation Posted 25/11/2022

Most viewed articles

About GaBI

Home/About GaBI Posted 06/08/2009

The best selling biotechnology drugs of 2008: the next biosimilars targets

Home/Reports Posted 14/10/2009

Global biosimilars guideline development – EGA’s perspective

Home/Guidelines Posted 28/09/2009

EU guidelines for biosimilars

Home/Guidelines Posted 08/10/2010